Top 10 ASX Dividend Stocks for Nov 2026 Download Free Report

1800-272-662
Shopping Cart 0
countryflagAU
Login

Home CompaniesTela Bio Inc

Tela Bio Inc

Healthcare Medical Devices
PortfolioPortfolio WatchlistWatchlist
Company price
0.9852 USD 0.04 ( 4.61%)
Last update at 2026-11-12T15:40:00Z
VOLUME
13434
Market Cap
49.21M

Momentum Score

…

TELA Bio, Inc., a commercial-stage medical technology company, focuses on providing soft-tissue reconstruction solutions that optimize clinical outcomes by prioritizing the preservation and restoration of the patient's anatomy. The company provides a portfolio of OviTex Reinforced Tissue Matrix (OviTex) products for hernia repair and abdominal wall reconstruction; and OviTex PRS Reinforced Tissue Matrix products to address the unmet needs in plastic and reconstructive surgery, as well as OviTex for Laparoscopic and Robotic Procedures, a sterile reinforced tissue matrix derived from ovine rumen with polypropylene, polyglycolic acid, and polylactic-co-glycolic acid designed to be used in laparoscopic and robotic-assisted hernia surgical repairs. It markets its products through a single direct sales force, principally in the United States. TELA Bio, Inc. was incorporated in 2012 and is headquartered in Malvern, Pennsylvania.

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Day Price Range
0.93
Low
1.03
High
52 Week Price Range
0.50
Low
1.69
High

Momentum Score

…
Loading momentum score…

A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.

Score - Rating
>= 1 - Low / > 1 but < 2 - Below Average / > 2 but < 3 - Average / > 3 but < 4 - Above Average / > 4 - High
AI Summary

Public information on Tela Bio Inc. (NASDAQ: TELA) is limited; the company operates in the medical technology sector focused on tissue repair and regenerative products. Its long-term growth could be driven by product commercialization, broader clinical adoption, and strategic partnerships that expand distribution, and investors may find the company attractive if it achieves consistent revenue growth and demonstrates clinical and operational execution.
Principal risks include clinical setbacks, the need for additional financing, intense competition in wound and surgical markets, and uncertain reimbursement and market access.

Risk Score
Medium

Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.

Key Metrics*

Previous Close
0.94
Dividend Yield
-
Revenue TTM
79.91M
Revenue Per Share
1.51
Gross Profit TTM
54.57M
Debt / Equity
8.82
ROE
-616.62%
Net Debt
4.81M
ROCE
-52.58%
Diluted EPS TTM
-0.82

Key Financials*

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Income before tax -38.60M -37.98M -46.66M -44.30M -33.28M
Net income -38.83M -37.84M -46.66M -44.34M -36.11M
Selling general administrative 15.69M 14.72M 14.89M 13.86M 12.46M
Selling and marketing expenses 63.18M 64.65M 59.68M 43.25M 29.06M
Gross profit 54.34M 46.49M 40.11M 27.04M 18.81M
Reconciled depreciation 1.01M 1.01M 0.85M 1.19M 0.54M
Ebit -33.36M -32.70M -41.44M -39.01M -29.45M
Ebitda -32.35M -31.68M -40.63M -39.02M -29.68M
Depreciation and amortization 1.01M 1.01M 0.81M -0.01M -0.23M
Non operating income net other - - - -1.24M -0.23M
Operating income -33.76M -34.12M -44.08M -39.01M -29.45M
Other operating expenses 114.03M 103.42M 102.53M 80.42M 58.91M
Interest expense 5.25M 5.29M 5.22M 4.05M 3.60M
Tax provision 0.23M -0.14M 0.00M - -
Net interest income -5.25M -5.29M -5.05M -4.05M -3.60M
Income tax expense 0.23M -0.14M 0.64M 0.04M 2.83M
Total revenue 80.28M 69.30M 58.45M 41.42M 29.46M
Total operating expenses 88.10M 80.60M 84.19M 66.05M 48.26M
Cost of revenue 25.93M 22.81M 18.34M 14.37M 10.65M
Total other income expense net -4.85M -3.87M -2.59M -5.29M -3.83M
Net income from continuing ops -38.83M -37.84M -43.75M -44.30M -33.28M
Net income applicable to common shares - - - -44.30M -33.28M
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Total assets 81.42M 87.33M 78.05M 67.86M 62.54M
Intangible assets 1.36M 1.74M 2.12M 2.50M 2.30M
Other current assets 3.37M 2.52M 2.10M 2.02M 3.23M
Total liab 75.11M 58.87M 59.17M 53.55M 42.45M
Total stockholder equity 6.31M 28.46M 18.88M 14.30M 20.10M
Other current liab 15.67M 12.91M 14.73M 10.53M 8.16M
Common stock 0.04M 0.04M 0.02M 0.02M 0.01M
Capital stock 0.04M 0.04M 0.02M 0.02M 0.01M
Retained earnings -397.56M -358.73M -320.89M -274.23M -229.93M
Other liab - - - - 0.38M
Cash 50.84M 52.67M 46.73M 42.02M 43.93M
Total current liabilities 17.98M 15.60M 16.97M 12.40M 10.57M
Net debt 4.81M -9.61M -3.95M -2.10M -12.44M
Short term debt - 0.55M 0.56M 0.34M -
Short long term debt total 55.65M 43.06M 42.78M 39.92M 31.49M
Other stockholder equity 403.74M 387.06M 339.65M 288.36M 250.06M
Property plant equipment - - - 1.68M 1.19M
Total current assets 75.58M 78.07M 71.73M 62.45M 59.05M
Net tangible assets - - - 11.81M 17.80M
Net receivables 10.35M 10.10M 9.74M 6.62M 4.23M
Long term debt 55.65M 41.12M 40.52M 39.92M 31.49M
Inventory 11.02M 12.78M 13.16M 11.79M 7.66M
Accounts payable 2.31M 2.15M 1.67M 1.53M 2.41M
Accumulated other comprehensive income 0.09M 0.09M 0.09M 0.15M -0.05M
Common stock total equity - - - 0.02M 0.01M
Retained earnings total equity - - - -274.23M -229.93M
Non currrent assets other 0.50M 2.54M 0.27M 1.23M -
Non current assets total 5.84M 9.25M 6.32M 5.41M 3.49M
Capital lease obligations 0.52M 0.55M 0.56M 0.34M -
Long term debt total - - - 39.92M 31.49M
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Investments - 4.45M -1.45M -1.87M -0.63M
Change to liabilities - - - 1.51M 4.27M
Total cashflows from investing activities 0.85M 4.45M -0.60M -1.87M -0.63M
Net borrowings 17.58M 0.00M 0.00M 6.54M 10.00M
Total cash from financing activities 25.75M 43.06M 46.27M 40.85M 0.58M
Change to operating activities - - - 4.04M 1.69M
Net income -38.83M -37.84M -46.66M -44.30M -33.28M
Change in cash -1.84M 5.94M 4.97M -1.91M -30.46M
Begin period cash flow 52.94M 46.99M 42.02M 43.93M 74.39M
End period cash flow 51.09M 52.94M 46.99M 42.02M 43.93M
Total cash from operating activities -28.22M -41.59M -40.86M -40.75M -30.43M
Issuance of capital stock 11.82M 42.92M 46.07M 34.40M 0.00M
Depreciation 1.01M 1.01M 0.81M 1.19M 0.54M
Other cashflows from investing activities 1.29M 5.44M 0.01M -1.00M -
Change to inventory -0.50M -2.97M -2.72M -6.07M -5.19M
Change to account receivables -0.11M -0.76M -3.06M -2.42M -1.55M
Sale purchase of stock 0.10M - -0.29M 0.05M 0.04M
Other cashflows from financing activities -0.20M 0.14M -0.07M 36.40M 0.55M
Change to netincome - - - 6.93M 5.78M
Capital expenditures 0.45M 0.99M 0.61M 1.87M 0.63M
Change receivables - - - -2.42M -1.55M
Cash flows other operating - - - 3.21M -0.69M
Cash and cash equivalents changes - - - -1.77M -30.47M
Change in working capital 1.50M -4.87M -1.67M -5.76M -3.47M
Stock based compensation 3.80M 4.36M 5.03M 3.99M 3.66M
Other non cash items 4.08M -4.12M 1.64M 4.13M 2.10M
Free cash flow -28.67M -42.58M -41.47M -42.62M -31.06M

Peer Comparison*

Sector: Healthcare Industry: Medical Devices

Stock Name
Change
(USD)
Price
(USD)
Trailing
PE (x)
Forward
PE (x)
Price Sales
TTM (x)
Price to Book Value (x)
Enterprise Value
to Revenue (x)
Enterprise Value
to EBITDA (x)
TELA
Tela Bio Inc		 0.04
4.61%		 0.99 - - 0.62 7.30 0.90 -5.01
ABT
Abbott Laboratories		 -0.71
0.65%		 108.58 25.97 17.24 3.57 3.20 3.81 16.75
MDT
Medtronic PLC		 0.28
0.28%		 101.89 26.60 15.87 3.35 2.08 3.90 14.12
SYK
Stryker Corporation		 -2.16
0.68%		 316.63 29.23 16.86 4.18 4.51 4.63 17.16
SEMHF
Siemens Healthineers AG		 -
-%		 47.31 39.57 21.32 3.01 3.29 2.95 16.92

Profile*

Tela Bio Inc

TELA Bio, Inc., a commercial-stage medical technology company, focuses on providing soft-tissue reconstruction solutions that optimize clinical outcomes by prioritizing the preservation and restoration of the patient's anatomy. The company provides a portfolio of OviTex Reinforced Tissue Matrix (OviTex) products for hernia repair and abdominal wall reconstruction; and OviTex PRS Reinforced Tissue Matrix products to address the unmet needs in plastic and reconstructive surgery, as well as OviTex for Laparoscopic and Robotic Procedures, a sterile reinforced tissue matrix derived from ovine rumen with polypropylene, polyglycolic acid, and polylactic-co-glycolic acid designed to be used in laparoscopic and robotic-assisted hernia surgical repairs. It markets its products through a single direct sales force, principally in the United States. TELA Bio, Inc. was incorporated in 2012 and is headquartered in Malvern, Pennsylvania.

1 Great Valley Parkway, Malvern, PA, United States, 19355

484 320 2930

https://www.telabio.com

218

Name Title Year Born
Mr. Antony Koblish Co-founder, Pres, CEO & Director 1966
Dr. E. Skott Greenhalgh Ph.D. Chief Technology Officer 1968
Mr. Peter C. Murphy Chief Commercial Officer 1973
Mr. Roberto E. Cuca J.D. CFO & COO 1968
Ms. Megan Smeykal VP, Corp. Controller, Chief Accounting Officer & Principal Accounting Officer 1976
Mr. D. Taylor Ocasio Gen. Counsel NA
Mr. Christopher H. Smith Sr. VP of Sales 1961
Ms. Jennifer Lou Armstrong Sr. VP of HR 1970
Mr. Michael Leonard Sr. VP of Technical Operations NA
Mr. Paul Talmo Chief Strategic Officer NA

Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

Kalkine

3 Mining Stock
Ideas Report

Download a free report with stock ideas and industry insights for general information.

Download Free Report Now → sector image

Top Stocks by Market Cap*

CU6
AUD 2.05
+23.49%
DMP
AUD 25.06
+12.93%
G6M
AUD 2.74
+10.93%
XRO
AUD 75.17
+6.08%
SGR
AUD 0.17
+6.06%
AXQ
AUD 3.07
-18.35%
BOE
AUD 1.50
-9.39%
GQG
AUD 0.71
-8.97%
MI6
AUD 0.81
-8.52%
ELV
AUD 3.73
-8.35%

Equity Sectors*

  • Basic Materials

    -3.09%

  • Communication Services

    +0.75%

  • Consumer Cyclical

    +0.43%

  • Consumer Defensive

    +0.12%

  • Energy

    -1.07%

  • Financial Services

    -0.02%

  • Healthcare

    +1.08%

  • Industrials

    -0.22%

  • Real Estate

    +0.61%

  • Technology

    -1.69%

  • Utilities

    -0.18%

Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.

Support

Hi! How can we help you today?

Loading…